- Home
- PETS vs CABA Comparison
PETS vs CABA Comparison
Compare PETS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | CABA |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 200.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PETS | CABA |
|---|---|---|
| Price | $3.01 | $2.38 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $3.20 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 6.9M | 2.3M |
| Earning Date | 02-02-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $0.99 |
| 52 Week High | $6.08 | $3.67 |
Technical Indicators
Market Signals| Indicator | PETS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 72.48 | 48.21 |
| Support Level | $1.69 | $2.32 |
| Resistance Level | $4.05 | $2.70 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 55.24 | 50.00 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.